{"release":"wpf-flagship-weight-management","version":"1.4.0","resultsSha256":"7015f8dd771509f9548e11fe120b65641159173a214b88ed02a6a90183b4538e","license":{"name":"Creative Commons Attribution 4.0 International","identifier":"CC-BY-4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"licenseScope":{"covered":["The stable result identifiers (resultId) and the WPF citation strings","WPF's classification of each study's design (kind)","WPF-written estimand summaries (estimand), the analysis-plan section pointers, and the study-specific limitations (limitations)","The field corrections and their basis notes, and the release changelog","The selection, arrangement and structure of the dataset, and its CSV, BibTeX and JSON renderings","WPF-authored verification records (verification): the locator descriptions, verification notes, automated-check descriptions and outcomes, the not-verified lists and WPF's paraphrased summary of the authors' stated limitations","The release metadata and checksum file"],"excluded":["The cited papers and their abstracts, figures and tables (publishers and authors)","Short quotations of third-party text inside verification records (quotedSourceText: registry outcome-measure titles and similar strings). They are marked as third-party","Third-party slide decks and other reproductions linked only as corroboration","ClinicalTrials.gov records, posted results, protocols and statistical analysis plans (linked, not redistributed)","Regulator documents and product labels","Bibliographic identifiers and reported numerical facts as stated by their sources","WPF branding, logos and names","WPF films, transcripts and website copy","WPF repository code"],"unclearAndExcluded":["Fields that closely restate source reports: population, comparator, endpoint, followUp, result, uncertainty, discontinuation, funder and trial names. Ownership of this wording is unresolved, so it is outside the licensed scope until the Owner decides otherwise."]},"suggestedAttribution":"World Peptide Foundation, \"WPF Flagship Weight Management\", version 1.4.0 (2026-11-14), https://www.worldpeptidefoundation.org/releases/wpf-flagship-weight-management/1.4.0/release.json. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Please indicate whether you made changes.","result":{"resultId":"surmount-5-weight-72w","candidateId":"semaglutide:1","kind":"direct_head_to_head","trial":"SURMOUNT-5 (phase 3b, open-label)","agents":"Tirzepatide vs semaglutide","pmid":"40353578","doi":"10.1056/NEJMoa2416394","registryId":"NCT05822830","population":"751 adults with obesity, without type 2 diabetes","comparator":"Maximum tolerated dose: tirzepatide 10 or 15 mg vs semaglutide 1.7 or 2.4 mg, once weekly","endpoint":"Percent change in weight from baseline to week 72","followUp":"72 weeks","result":"-20.2% with tirzepatide vs -13.7% with semaglutide (least-squares means; P<0.001)","uncertainty":"95% CI -21.4 to -19.1 (tirzepatide); -14.9 to -12.6 (semaglutide)","discontinuation":"Handled by the primary estimand: participants stay in the analysis regardless of stopping the study drug or taking other anti-obesity medication, except switching to the other study drug. Registry participant flow counts study completion, not stopping the drug: 319 of 375 (tirzepatide) and 319 of 376 (semaglutide) completed the study. The registry posts no count of participants who stopped the drug and stayed in the study.","funder":"Eli Lilly","registryResultsPosted":true,"registryMasking":"None (open-label)","estimand":"Modified treatment-regimen estimand (the plan's primary): participants included regardless of treatment discontinuation or other anti-obesity medication, except switching to the other study drug. The displayed -20.2% and -13.7% match the registry's ANCOVA result over the full analysis set, which is the method the plan specifies for this estimand (§4.3.1); the publication abstract does not name the estimand, so this is verified by method, not by an explicit label.","analysisPlan":{"title":"SURMOUNT-5 Statistical Analysis Plan v3 (approved 23 Oct 2024), ClinicalTrials.gov NCT05822830","url":"https://cdn.clinicaltrials.gov/large-docs/30/NCT05822830/SAP_001.pdf","sections":"§1.1 Primary estimand; §4.3.1 primary analysis; §4.3.2 efficacy-estimand analysis"},"limitations":["Open-label: participants and investigators knew the assigned drug (registry masking: none).","Compared maximum tolerated doses; the results apply to adults with obesity without type 2 diabetes.","Funded by the manufacturer of tirzepatide."],"citation":"SURMOUNT-5 (phase 3b, open-label). Tirzepatide vs semaglutide. Primary source: https://doi.org/10.1056/NEJMoa2416394 (PMID 40353578; NCT05822830). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.4.0, result surmount-5-weight-72w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=surmount-5-weight-72w | Result link: https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-5-weight-72w","releaseVersion":"1.4.0","designLabel":"Direct head-to-head randomized trial","designExplanation":"Participants in one trial were randomly assigned to tirzepatide or semaglutide, so the difference between the two arms is a direct randomized comparison.","verification":{"verifiedOn":"2026-11-14","locators":[{"claim":"-20.2% with tirzepatide and -13.7% with semaglutide at week 72","source":"ClinicalTrials.gov results","role":"primary","locator":"Record NCT05822830, Results tab, primary outcome measure 1 (percent change in body weight, baseline to week 72): the tirzepatide arm posts -20.2 and the semaglutide arm posts -13.7, as least-squares means.","url":"https://clinicaltrials.gov/study/NCT05822830?tab=results#outcome-measures","status":"matched","method":"scripted","checkId":"ctgov-surmount5-arms","note":"The registry posts standard errors, not the confidence intervals shown on this page.","quotedSourceText":["Percent Change From Baseline in Body Weight"]},{"claim":"95% confidence intervals -21.4 to -19.1 and -14.9 to -12.6; P<0.001","source":"PubMed abstract","role":"primary","locator":"Abstract, Results paragraph: reports the week-72 least-squares mean change as -20.2% (95% CI -21.4 to -19.1) for tirzepatide and -13.7% (95% CI -14.9 to -12.6) for semaglutide, P<0.001, among 751 randomized participants.","url":"https://pubmed.ncbi.nlm.nih.gov/40353578/#abstract","status":"matched","method":"scripted","checkId":"pubmed-surmount5"},{"claim":"Primary estimand and the method that produces the displayed values","source":"Statistical analysis plan","role":"primary","locator":"SAP version 3 (approved 23 Oct 2024): section 1.1 defines the primary estimand and section 4.3.1 specifies the primary analysis.","url":"https://cdn.clinicaltrials.gov/large-docs/30/NCT05822830/SAP_001.pdf","status":"matched","method":"document_read","note":"The abstract does not name the estimand. The displayed values match the registry's ANCOVA result over the full analysis set, which is the method the plan specifies for its primary (modified treatment-regimen) estimand, so the match is by method, not by an explicit label."},{"claim":"Study completion by arm, which is how the registry reports leaving the study","source":"ClinicalTrials.gov results","role":"primary","locator":"Record NCT05822830, Results tab, participant flow, overall study period: 375 participants started on tirzepatide and 376 on semaglutide, and 319 in each arm completed the study (56 and 57 did not). Recorded reasons for not completing, tirzepatide then semaglutide: withdrawal by subject 27 and 26, lost to follow-up 16 and 18, adverse event 6 and 6, assigned treatment by mistake 5 and 3, pregnancy 1 and 2, non-compliance with study drug 1 and 1, out of the country 0 and 1. This counts leaving the study. It is not a count of stopping the study drug while staying in the study, which the registry does not post.","url":"https://clinicaltrials.gov/study/NCT05822830?tab=results","status":"matched","method":"scripted","checkId":"ctgov-surmount5-flow"},{"claim":"Table or figure in the published paper that shows the displayed numbers","source":"Publisher page","role":"primary","locator":"Publisher article page reached through the DOI 10.1056/NEJMoa2416394","url":"https://doi.org/10.1056/NEJMoa2416394","status":"not_read","method":"document_read","note":"An automated request to this address returned HTTP 403 on 2026-11-12, which shows the request was blocked; it does not show why. Europe PMC lists no open-access full text for this paper, and WPF has not established whether the article sits behind a paywall. No table or figure number is claimed."}],"unverified":["The table or figure in the published paper that shows these numbers: not located, because the publisher page could not be read.","Treatment-discontinuation counts (stopping the study drug but staying in the study) for each arm: the registry participant flow reports study completion only, and the full text was not read.","The authors' own limitations and disclosure statements: not reviewed, because the full text could not be read."],"automatedChecks":[{"id":"pubmed-surmount5","what":"The abstract reports the displayed point estimates, both confidence intervals and the sample size.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the PubMed record and compares the extracted abstract with the displayed values.","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"},{"id":"ctgov-surmount5-flow","what":"The registry participant flow posts 375 and 376 started and 319 and 319 completed for the two arms.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): reads the ClinicalTrials.gov API v2 participant flow and compares the started and completed counts of both groups.","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"},{"id":"ctgov-surmount5-arms","what":"The registry's primary outcome measure 1 (week 72) posts both displayed arm values.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): reads the ClinicalTrials.gov API v2 results record and compares posted values numerically.","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"}],"humanReview":"none recorded"},"versionedRecordUrl":"https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=surmount-5-weight-72w","analysisPlanUrl":"https://cdn.clinicaltrials.gov/large-docs/30/NCT05822830/SAP_001.pdf","analysisPlanSections":"§1.1 Primary estimand; §4.3.1 primary analysis; §4.3.2 efficacy-estimand analysis","registryCheckedOn":"2026-11-11","detailUrl":"https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-5-weight-72w"}}